Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

STAR: ultrafast universal RNA-seq aligner

Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179

The Molecular Signatures Database Hallmark Gene Set Collection

Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049

Adjusting batch effects in microarray expression data using empirical Bayes methods

Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658

METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression

Liu, Z., Sun, T., Piao, C., Zhang, Z., & Kong, C. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02879-2 · Cited by 28

Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma

Zengin, Z. B., Weipert, C. M., Salgia, N., Dizman, N., Hsu, J., Meza, L., Chehrazi‐Raffle, A., Muddasani, R., Salgia, S. K., Malhotra, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0572 · Cited by 29

Typical tumor immune microenvironment status determine prognosis in lung adenocarcinoma

Ren, C., Li, J., Zhou, Y., Zhang, S., & Wang, Q. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101367 · Cited by 28

EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma

Dou, S., Zhang, L., Wang, C., Yao, Y., Jiang, W. H., Ye, L., Li, J., Wu, S., Sun, D., Gong, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.813732 · Cited by 28

(mis)-Targeting of SWI/SNF complex(es) in cancer

Reddy, D., Bhattacharya, S., & Workman, J. L. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10102-5 · Cited by 30

A Predictive Network‐Based Immune Checkpoint Blockade Immunotherapeutic Signature Optimizing Patient Selection and Treatment Strategies

Zhang, N., Yang, M., Yang, J., Zhang, C., & Guo, A. (2024) · Small Methods · doi:10.1002/smtd.202301685 · Cited by 27

von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME

Tedesco, L., Elguero, B., Gonilski‐Pacin, D., Senin, S. A., Pollak, C., Marchiñena, P. A. G., Jurado, A. M., Isola, M., Labanca, M. J., Palazzo, M., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1507-3 · Cited by 29

Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates

Yang, Q., Shen, R., Xu, H., Shi, X., Xu, L., Zhang, L., Fan, X., & Jin, X. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-289 · Cited by 28

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers

Labadie, B. W., Balar, A. V., & Luke, J. J. (2021) · Cancers · doi:10.3390/cancers13215415 · Cited by 30

ParsVNN: parsimony visible neural networks for uncovering cancer-specific and drug-sensitive genes and pathways

Huang, X., Huang, K., Johnson, T. S., Radovich, M., Zhang, J., Ma, J., & Wang, Y. (2021) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqab097 · Cited by 26

PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner

Zhou, M., Leung, J. Y., Gessner, K. H., Hepperla, A. J., Simon, J. M., Davis, I. J., & Kim, W. Y. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0480 · Cited by 26

A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma

Gao, J., Ye, F., Han, F., Jiang, H., & Zhang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956679 · Cited by 29

Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer

Hargadon, K. M. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04689-9 · Cited by 30

Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma

Ferguson, L. P., Gatchalian, J., McDermott, M. L., Nakamura, M., Chambers, K. R., Rajbhandari, N., Lytle, N. K., Rosenthal, S. B., Hamilton, M., Albini, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35796-7 · Cited by 27

Patient Stratification of Clear Cell Renal Cell Carcinoma Using the Global Transcription Factor Activity Landscape Derived From RNA-Seq Data

Zhu, Y., Cang, S., Chen, B., Gu, Y., Jiang, M., Yan, J., Shao, F., & Huang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.526577 · Cited by 25

Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma

Tian, J., Luo, J., Zeng, X., Ke, C., Wang, Y., Liu, Z., Li, L., Zhang, Y., Hu, Z., & Yang, C. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008226 · Cited by 28

Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy

Liu, Y., Xu, C., Zhang, L., Xu, G., Yang, Z., Xiang, L., Jiao, K., Chen, Z., Zhang, X., & Liu, Y. (2024) · Science Advances · doi:10.1126/sciadv.adi7764 · Cited by 27

Prognostic value of infiltrating immune cells in clear cell renal cell carcinoma (ccRCC)

Liu, S., Li, S., Wang, Y., Wang, F., Zhang, L., Xian, S., Yang, D., Yuan, M., Dai, F., Zhao, X., et al. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29479 · Cited by 26

ARID2 Chromatin Remodeler in Hepatocellular Carcinoma

Loesch, R., Chenane, L., & Colnot, S. (2020) · Cells · doi:10.3390/cells9102152 · Cited by 26

Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need

Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 26

LncRNA HIF1A-AS2 accelerates malignant phenotypes of renal carcinoma by modulating miR-30a-5p/SOX4 axis as a ceRNA

Chen, M., Wei, X., Shi, X., Lu, L., Zhang, G., Huang, Y., & Hou, J. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0209 · Cited by 25

Upregulation of ARNTL2 is associated with poor survival and immune infiltration in clear cell renal cell carcinoma

Wang, S., Ma, X., Ying, Y., Sun, J., Yang, Z., Li, J., Jin, K., Wang, X., Xie, B., Zheng, X., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02046-z · Cited by 26

Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma

Attalla, K., DiNatale, R. G., Rappold, P. M., Fong, C. J., Sánchez-Vega, F., Silagy, A. W., Weng, S., Coleman, J., Lee, C., Carlo, M. I., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4058 · Cited by 27

Altered regulation of DPF3, a member of the SWI/SNF complexes, underlies the 14q24 renal cancer susceptibility locus

Colli, L. M., Jessop, L., Myers, T. A., Camp, S. Y., Machiela, M. J., Choi, J., Cunha, R., Onabajo, O. O., Mills, G. C., Schmid, V., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.07.009 · Cited by 27

IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer

Yi, X., Zheng, X. S., Xu, H., Li, J., Zhang, T., Ge, P., Liao, D., Li, H., Lyu, X., & Ai, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898493 · Cited by 26

Lack of clinical activity with crizotinib in a patient with FUS rearranged rhabdomyosarcoma with ALK protein overexpression

Lewin, J. H., Desai, J., Smith, K. M., Luen, S., & Wong, D. (2019) · Pathology · doi:10.1016/j.pathol.2019.07.004 · Cited by 26

Crosstalk between hypoxia-induced pyroptosis and immune escape in cancer: From mechanisms to therapy

Meybodi, S. M., Ejlalidiz, M., Manshadi, M. R., Raeisi, M., Zarin, M., Kalhor, Z., Saberiyan, M., & Hamblin, M. R. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104340 · Cited by 24

Increased spatial coupling of integrin and collagen IV in the immunoresistant clear-cell renal-cell carcinoma tumor microenvironment

Soupir, A. C., Hayes, M. T., Peak, T. C., Ospina, O. E., Chakiryan, N. H., Berglund, A., Stewart, P. A., Nguyen, J. V., Segura, C. M., Francis, N. L., et al. (2024) · Genome biology · doi:10.1186/s13059-024-03435-z · Cited by 25

Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma

Motzer, R. J., Porta, C., Eto, M., Hutson, T. E., Rha, S. Y., Merchan, J. R., Winquist, E., Gurney, H., Grünwald, V., George, S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.12.003 · Cited by 26

Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis

Tang, T., Huang, X., Zhang, G., Lu, M., Hong, Z., Wang, M., Huang, J., Zhi, X., & Liang, T. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004129 · Cited by 25

Association of KDR Mutation With Better Clinical Outcomes in Pan-Cancer for Immune Checkpoint InhibitorsPreprint

Cui, Y., Zhang, P., Liang, X., Xu, J., Liu, X., Wu, Y., Zhang, J., Wang, W. T., Zhang, F., & Guo, R. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3991639 · Cited by 26

A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer

Ding, K., He, Y., Wei, J., Fu, S., Wang, J., Chen, Z., Zhang, H., Qu, Y., Liang, K., Gong, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943090 · Cited by 23

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma

Deutsch, J. S., Lipson, E. J., Danilova, L., Topalian, S. L., Jedrych, J. J., Baraban, E. G., Ged, Y. M. A., Singla, N., Choueiri, T. K., Gupta, S. K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100947 · Cited by 25

A protein sequence-based deep transfer learning framework for identifying human proteome-wide deubiquitinase-substrate interactions

Liu, Y., Li, D., Zhang, X., Xia, S., Qu, Y., Li, Y., Li, Y., Kong, X., Zhang, L., Cui, C.-P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48446-3 · Cited by 24

Unraveling LGALS1 as a Potential Immune Checkpoint and a Predictor of the Response to Anti-PD1 Therapy in Clear Cell Renal Carcinoma

Li, Y., Yang, S., Yue, H., Yuan, D., Li, L., Zhao, J., & Zhao, L. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00710-4 · Cited by 26

TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, p53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell Carcinoma

Sekino, Y., Han, X., Babasaki, T., Miyamoto, S., Kitano, H., Kobayashi, G., Goto, K., Inoue, S., Hayashi, T., Teishima, J., et al. (2020) · Oncology · doi:10.1159/000506775 · Cited by 25

A method for predicting drugs that can boost the efficacy of immune checkpoint blockade

Xia, Y., Li, X., Bie, N., Pan, W., Miao, Y., Yang, M., Gao, Y., Chen, C., Liu, H., Gan, L., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01789-x · Cited by 24

Transcriptomic characterization and innovative molecular classification of clear cell renal cell carcinoma in the Chinese population

Zhao, Q., Jia, X., Hong, B., Qian, W., Liu, T., Fan, B., Cai, J., Ji, Y., Liu, J., Yang, Y., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01552-w · Cited by 24

High Expression of CD39 is Associated with Poor Prognosis and Immune Infiltrates in Clear Cell Renal Cell Carcinoma

Wu, J., Wang, Y.-C., Xu, W., Luo, W.-J., Wan, F., Zhang, H., Ye, D., Qu, Y.-Y., & Zhu, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s272553 · Cited by 27

Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study

Herrmann, T., Ginzac, A., Molnar, I., Bailly, S., Durando, X., & Mahammedi, H. (2021) · Cancer Medicine · doi:10.1002/cam4.4208 · Cited by 25

From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma

Anker, J. F., Miller, J. R., Taylor, N., Kyprianou, N., & Tsao, C. (2021) · Cells · doi:10.3390/cells10113231 · Cited by 26

Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: A systematic review and meta-analysis

Wang, N., Qin, Y., Du, F., Wang, X., & Song, C. (2022) · Gene · doi:10.1016/j.gene.2022.146638 · Cited by 24

Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening

Shishodia, S., Nuñez, R., Strohmier, B. P., Bursch, K. L., Goetz, C. J., Olp, M. D., Jensen, D. R., Fenske, T. G., Ordonez‐Rubiano, S. C., Blau, M. E., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00864 · Cited by 24

Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response

Zeng, Z., Gu, S. S., Wong, C. J., Yang, L., Ouardaoui, N., Li, D., Zhang, W., Brown, M. A., & Liu, X. S. (2022) · Science Advances · doi:10.1126/sciadv.abm8564 · Cited by 25

YAP-Activated SATB2 Is a Coactivator of NRF2 That Amplifies Antioxidative Capacity and Promotes Tumor Progression in Renal Cell Carcinoma

Jin, J., Chen, F., He, W., Zhao, L., Lin, B., Zheng, D., Chen, L., He, H., & He, Q. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1693 · Cited by 24

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers

Dai, J., Cui, Y., Xiao, L., Xu, J., Li, J., Chen, Y., Zhang, E., & Guo, R. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1066347 · Cited by 26

Potentiating anti-tumor immunity by re-engaging immune synapse molecules

Zhou, X., Xu, T., Li, C., He, Y., Hu, Y., Gong, H., Li, J., Jiang, H., Wen, L., Fu, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101975 · Cited by 23

Integrated Genomic Characterization of the Human Immunome in Cancer

Li, Y., Triplett, T., Burgman, B., Sun, M., McGrail, D. J., Qi, D., Shukla, S., Wu, E., Wu, C. J., Capasso, A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0384 · Cited by 23

Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?

Guida, A., Sabbatini, R., Gibellini, L., Biasi, S. D., Cossarizza, A., & Porta, C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102157 · Cited by 23

Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer

Shulman, M., Shi, R., & Zhang, Q. H. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.05.016 · Cited by 23

Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?

Jonasch, E. W., Atkins, M. B., Chowdhury, S., & Mainwaring, P. N. (2022) · Cancers · doi:10.3390/cancers14030644 · Cited by 23

Immunometabolic coevolution defines unique microenvironmental niches in ccRCC

Tang, C., Xie, A. X., Liu, E., Kuo, F., Kim, M., Dinatale, R., Golkaram, M., Chen, Y.-B., Gupta, S., Motzer, R., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.005 · Cited by 25

Collaborative privacy-preserving analysis of oncological data using multiparty homomorphic encryption

Geva, R., Gusev, A., Polyakov, Y., Liram, L., Rosolio, O., Alexandru, A. B., Genise, N., Blatt, M., Duchin, Z., Waissengrin, B., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2304415120 · Cited by 28

Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma

Gao, X. Y., & McDermott, D. F. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000323 · Cited by 23

CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients

Liu, T., Xia, Q., Zhang, H., Wang, Z., Yang, W., Gu, X., Hou, T., Chen, Y., Pei, X., Zhu, G., et al. (2020) · Aging · doi:10.18632/aging.103999 · Cited by 23

Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma

Pourmir, I., Noel, J., Simonaggio, A., Oudard, S. M., & Vano, Y. A. (2021) · World Journal of Urology · doi:10.1007/s00345-020-03528-x · Cited by 23

Generalizable AI predicts immunotherapy outcomes across cancers and treatments

Shen, W. X., Moon, I., Nguyen, T. H., Li, M. M., Huang, Y., Nair, N., Marbach, D., & Žitnik, M. (2026) · Nature Medicine · doi:10.1038/s41591-026-04502-7 · Cited by 32

Tumor cell heterogeneity and resistance; report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting

Miyahira, A. K., Den, R. B., Carlo, M. I., de Leeuw, R., Hope, T. A., Karzai, F. H., McKay, R. R., Salami, S. S., Simons, J. W., Pienta, K. J., et al. (2018) · The Prostate · doi:10.1002/pros.23729 · Cited by 24

Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab

Ueda, K., Suekane, S., Kurose, H., Ogasawara, N., Hiroshige, T., Chikui, K., Uemura, K., Nakiri, M., Nishihara, K., Matsuo, M., et al. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab157 · Cited by 22

Novel emerging biomarkers to immunotherapy in kidney cancer

Ged, Y. M. A., & Voss, M. H. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211059367 · Cited by 21

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Choueiri, T. K., Albiges, L. K., Atkins, M. B., Bakouny, Z., Bratslavsky, G., Braun, D. A., Haas, N. B., Haanen, J. B. A. G., Hakimi, A. A., Jewett, M. A. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3238 · Cited by 22

Transcriptional determinants of cancer immunotherapy response and resistance

Gupta, R., Mehta, A., & Wajapeyee, N. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.01.008 · Cited by 23

An immunotherapy response prediction model derived from proliferative CD4+ T cells and antigen-presenting monocytes in ccRCC

Zheng, K. C., Gao, L., Hao, J., Zou, X., & Hu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.972227 · Cited by 23

Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma

Dong, P., Zhang, X., Peng, Y., Zhang, Y., Liu, R., Li, Y., Pan, Q., Wei, W., Guo, S., Zhang, Z., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1279 · Cited by 23

Non‐SMC condensin I complex subunit H participates in anti‐programmed cell death‐1 resistance of clear cell renal cell carcinomas

Chen, Z., Ruan, W., Guo, C., Chen, K., Li, L., Tian, J., Hu, Z., Peng, D., & Zeng, X. (2023) · Cell Proliferation · doi:10.1111/cpr.13400 · Cited by 22

Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma

Martin, S. D., Bhuiyan, I., Soleimani, M., & Wang, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12154987 · Cited by 23

Genomic and epigenomic integrative subtypes of renal cell carcinoma in a Japanese cohort

Fukagawa, A., Hama, N., Totoki, Y., Nakamura, H. K., Arai, Y., Saito-Adachi, M., Maeshima, A. M., Matsui, Y., Yachida, S., Ushiku, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44159-1 · Cited by 19

Predictors of disease aggressiveness influence outcome from immunotherapy treatment in renal clear cell carcinoma

Kamal, Y., Cheng, C., Frost, H. R., & Amos, C. I. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1500106 · Cited by 23

MELK is Upregulated in Advanced Clear Cell Renal Cell Carcinoma and Promotes Disease Progression by Phosphorylating PRAS40

Zhang, H., Wei, P., Lv, W., Han, X., Yang, J., Qin, S., & Zhang, Y. (2019) · Cell Transplantation · doi:10.1177/0963689719890860 · Cited by 22

Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer

Chakraborty, A. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.012 · Cited by 23

Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer

Hänze, J., Wegner, M., Noeßner, E., Hofmann, R. W., & Hegele, A. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00728-8 · Cited by 22

PD‐1/PD‐L1 inhibitors‐based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies

Ding, L., Dong, H., Zhou, T. R., Wang, Y. H., Yan, T., Li, J. C., Wang, Z. Y., Liang, C., & Liang, C. (2021) · Cancer Medicine · doi:10.1002/cam4.4190 · Cited by 21

T-cell receptor V and J usage paired with specific HLA alleles associates with distinct cervical cancer survival rates

Roca, A. M., Chobrutskiy, B. I., Callahan, B. M., & Blanck, G. (2019) · Human Immunology · doi:10.1016/j.humimm.2019.01.005 · Cited by 25

Multifunctional Biomimetic Nanocarriers for Dual‐Targeted Immuno‐Gene Therapy Against Hepatocellular Carcinoma

Sun, Y., Liu, Y., Li, R., Zhang, C., Wu, M., Zhang, X., Zheng, A., Liao, N., Zheng, Y., Xu, H., et al. (2024) · Advanced Science · doi:10.1002/advs.202400951 · Cited by 21

Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy

Song, Y., Li, Z., Xue, W., & Zhang, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0173 · Cited by 21

An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer

Dawson, N. A., Zibelman, M. R., Lindsay, T., Feldman, R. A., Saul, M. E., Gatalica, Z., Korn, W. M., & Heath, E. I. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0531 · Cited by 23

Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma

Chakiryan, N. H., Hajiran, A. J., Kim, Y., Aydın, A. M., Zemp, L. W., Katende, E. N., Nguyen, J. V., Fan, W., Cheng, C., Lopez-Blanco, N., et al. (2021) · European Urology Focus · doi:10.1016/j.euf.2021.04.014 · Cited by 22

Prognostic Value of an m5C RNA Methylation Regulator-Related Signature for Clear Cell Renal Cell Carcinoma

Li, H., Jiang, H., Huang, Z., Chen, Z., & Chen, N. (2021) · Cancer Management and Research · doi:10.2147/cmar.s323072 · Cited by 21

Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review

Kim, T. J., Lee, Y. H., & Koo, K. C. (2022) · Korean journal of urology · doi:10.4111/icu.20220103 · Cited by 22

Modulation of T cell function and survival by the tumor microenvironment

Mani, N. L., Andrews, D., & Obeng, R. C. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1191774 · Cited by 22

New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)

Wang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 22

Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma

D’Costa, N. M., Cina, D., Shrestha, R., Bell, R. H., Lin, Y., Asghari, H., Monjarás-Ávila, C. U., Kollmannsberger, C., Hach, F., Chavez-Munoz, C. I., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58804-y · Cited by 21

How Project Leaders Can Overcome the Crisis of Silence

Grenny, J., Maxfield, D. G., & Shimberg, A. (2007) · Dialnet (Universidad de la Rioja) · Cited by 21

PBAF loss leads to DNA damage-induced inflammatory signaling through defective G2/M checkpoint maintenancePreprint

Feng, H., Lane, K. A., Roumeliotis, T. I., Jeggo, P. A., Somaiah, N., Choudhary, J. S., & Downs, J. A. (2022) · Genes & Development · doi:10.1101/gad.349249.121 · Cited by 23

Characteristics of the tumor microenvironment and potential immunotherapy strategies in renal cell carcinoma

Wen, H., Shi, Z., Zhu, X., Wang, L., & Chen, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643533 · Cited by 21

Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer

Kinoshita, T., Terai, H., & Yaguchi, T. (2021) · Life · doi:10.3390/life11101029 · Cited by 23

Tumor evolution selectively inactivates the core microRNA machinery for immune evasion

Song, T., Long, M., Zhao, H., Zou, M.-W., Fan, H., Liu, Y., Geng, C., Song, M., Liu, Y.-F., Chen, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27331-3 · Cited by 20

Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma

Liao, X., Xia, X., Su, W. C., Yan, H., Ma, Y., Xu, L., Luo, H., Liu, W., Yin, D., Zhang, W., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.01.036 · Cited by 20

Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma

Teng, J., Zhou, K., Lv, D., Wu, C., & Feng, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.714408 · Cited by 20

Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer

Shin, D. S., Park, K., Garon, E. B., & Dubinett, S. M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.005 · Cited by 20

Inter- and intra-tumor heterogeneity of genetic and immune profiles in inherited renal cell carcinoma

Tabata, M., Sato, Y., Kogure, Y., McClure, M. B., Oshikawa-Kumade, Y., Saito, Y., Shingaki, S., Ito, Y., Yuasa, M., Koya, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112736 · Cited by 19

Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma

Astore, S., Baciarello, G., Cerbone, L., & Calabrò, F. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.33 · Cited by 20

Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment

Chaudhri, A., Lizee, G. A., Hwu, P., & Rai, K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2244 · Cited by 21

FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer

Li, H., Zheng, N., Guo, A., Tang, W., Li, M., Cao, Y., Ma, X., Cao, H., Ma, Y., Wang, H., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06469-0 · Cited by 22

MDK promotes M2 macrophage polarization to remodel the tumour microenvironment in clear cell renal cell carcinoma

Shi, N., Chen, S., Wang, D., Wu, T., Zhang, N., Chen, M., & Ding, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-69183-z · Cited by 22

Cancer research in the era of immunogenomics

Wolf, Y., & Samuels, Y. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000475 · Cited by 20

Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinants of response

Murphy, C., Muscat, A. M., Ashley, D. M., Mukaro, V. R., West, L., Liao, Y., Chisanga, D., Shi, W., Collins, I. M., Baron-Hay, S. E., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210891 · Cited by 22

Artificial intelligence–enabled multi-omics biomarkers for immune checkpoint blockade: mechanisms, predictive modeling, and clinical translation

Wang, X., Xiong, D., Cui, S., Duan, B., Ding, G., Huang, Y., & Wang, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1732079 · Cited by 22

Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions

Khaleel, S. S., Katims, A., Cumarasamy, S., Rosenzweig, S. J., Attalla, K., Hakimi, A. A., & Mehrazin, R. (2022) · Cancers · doi:10.3390/cancers14092085 · Cited by 22

Precision Medicine in Cholangiocarcinoma: Past, Present, and Future

Cheng, C.-Y., Chen, C., & Wu, C. (2022) · Life · doi:10.3390/life12060829 · Cited by 19

A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852

Highlights from Recent Cancer Literature

(2018) · Cancer Research · doi:10.1158/0008-5472.1373.78.6

PBRM1 loss promotes tumour response to immunotherapy

Otto, G. P. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2018.7 · Cited by 5

Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma.

Miao, D., Margolis, C. A., Martini, D. J., Mullane, S. A., Cullen, D., Horak, C. E., Wind‐Rotolo, M., Hellmann, M. D., Voss, M. H., Motzer, R. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3016 · Cited by 4

Abstract B48: PBRM1 loss promotes resistance to immunotherapy in RCC

Liu, X., Kong, W., Hoang, A. G., Zhang, X., Zhou, L., Pilie, P. G., Isgandrova, S., Moczygemba, M. M., & Jonasch, E. W. (2020) · Cancer Immunology Research · doi:10.1158/2326-6074.tumimm18-b48